Clinical trials: End Stage Heart Disease
End Stage Renal Disease, Congestive Heart Failure
Spironolactone Safety in Dialysis Patients
Cardiovascular disease is the leading cause of death and disproportionately prevalent in patients with kidney disease. Spironolactone has been shown to improve survival in the general population with heart failure by up to 30%.
- Trial name
- NCT00328809
- Testing
- spironolactone
- Where
- United States
- Sponsor
- State University of New York - Upstate Medical University
Sudden Cardiac Death, End Stage Renal Disease
T-Wave Alternans in Dialysis Patients
Sudden cardiac death due to arrhythmia is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis (HD).
- Trial name
- NCT00621426
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Kidney Disease, Peritoneal Dialysis (PD)
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.
- Conditions
- Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
- Trial name
- SCALE-PD (NCT07059962)
- Testing
- Bodyport Cardiac Scale
- Where
- 7 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- Bodyport Inc.
Cardiac Disease
DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as…
- Trial name
- BENEFIT1 (NCT03571672)
- Testing
- DEFINITY
- Where
- 9 sites in United States
- Volunteers
- 153 people
- Sponsor
- Lantheus Medical Imaging
Renal Failure, Left Ventricular Hypertrophy
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic…
- Trial name
- NCT00602004
- Testing
- losartan
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Melbourne Health
End-Stage Heart Failure, Cardiomyopathies
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
The purpose of this trial is to determine the safety and feasibility of the VentrAssist LVAD in providing circulatory support for patients who require an LVAD as a bridge to cardiac transplantation.
- Trial name
- NCT00490347
- Testing
- VentrAssist Left Ventricular Assist Device
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ventracor
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Heart Failure, Congestive
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
Heart failure is a condition in which the heart is unable to pump enough blood to the body's other organs. A heart transplant may be necessary for some individuals with end-stage heart failure.
- Trial name
- NCT00383630
- Testing
- Intramyocardial injection of bone marrow mononuclear cells, Intramyocardial injection of CD34+ selected bone marrow mononuclear cells, LVAD alone
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Emergencies, Heart Diseases
Evaluate the Predictive Impact of the EHMRG
External validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
- Trial name
- EHMRGscore (NCT05632263)
- Testing
- EHMRGscore
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
End-stage Renal Disease
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
This study aims mainly to investigate the effects of two approaches to control blood pressure in hypertensive hemodialysis patients; using antihypertensive drugs versus strict volume control (by strict dietary salt restriction…
- Trial name
- NCT00307463
- Testing
- strict volume control policy, antihypertensive drugs administration
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 258 people
- Sponsor
- Ege University
End Stage Kidney Disease, Fibrosis Myocardial
Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1…
- Trial name
- CONFIRM (NCT03586518)
- Testing
- Cardiac MRI scan, Echocardiogram, Cardiac explantation
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Leicester
Heart Failure, Acute Coronary Syndromes
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）
The aim of the study is to evaluate diagnostic performance of N-terminal Brain natriuretic Peptide (NT-proBNP) in acute heart failure among Chinese population.
- Trial name
- NT-proBNP，HF (NCT06691477)
- Testing
- No Interventions
- Where
- 4 sites in China
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Primary Amyloidosis of Light Chain Type
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.
- Trial name
- DIACAL (NCT01531751)
- Testing
- High Cut-off Hemodialysis, Chemotherapy
- Where
- Italy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Failure, Systolic, Renal Disease, End Stage
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to…
- Conditions
- Heart Failure, Systolic, Renal Disease, End Stage, Chronic Kidney Diseases
- Trial name
- E-HART (NCT03062176)
- Testing
- Anakinra
- Sponsor
- Virginia Commonwealth University
Heart Failure, End-stage Disease
Proactive Palliative Care for Patients With Ventricular Assist Devices (VAD) and Their Families
The primary aim of the study is to provide "proof of concept" to demonstrate that patients with Ventricular Assist Devices (VADs) and caregivers are willing to be enrolled in a randomized trial of palliative care and that such a…
- Trial name
- NCT01427634
- Testing
- Palliative Care, Usual Care
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
End Stage Renal Disease, Coronary Artery Disease
Coronary Artery Disease Screening in Kidney Transplant Candidates
Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown.
- Trial name
- CADScreening (NCT02082483)
- Testing
- Selective Screening
- Where
- 6 sites in Canada
- Volunteers
- 144 people
- Sponsor
- University of British Columbia
End Stage Chronic Renal Failure, Congestive Heart Failure (CHF)
The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion
The purpose of this study is to evaluate whether a personalized, high-rate fluid removal strategy guided by ultrasound is as safe and effective as the standard fluid removal rate for patients with advanced kidney disease who are…
- Conditions
- End Stage Chronic Renal Failure, Congestive Heart Failure (CHF), Intravascular Congestion, Fluid Overload
- Trial name
- FILTRATE (NCT07705269)
- Testing
- High-rate ultrafiltration, Standard fluid removal
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Liver Transplantation, End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL) - Pilot
Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial.
- Trial name
- REFIL-1 (NCT05647733)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Optimized cardiac output liberal fluid management strategy, Phlebotomy
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)